This is a preview of subscription content, log in via an institution to check access.
Notes
incremental cost-effectiveness ratio
Reference
Deuffic-Burban S, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 12188). Journal of Hepatology : 17 Mar 2014. Available from: URL: http://doi.org/10.1016/j.jhep.2014.03.011
Rights and permissions
About this article
Cite this article
IFN-free hep C treatment effective, but costs bring uncertainty. PharmacoEcon Outcomes News 700, 8 (2014). https://doi.org/10.1007/s40274-014-1172-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-014-1172-9